KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Operations: 2009-2025

Historic Cash from Operations for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $107.8 million.

  • Novavax's Cash from Operations rose 174.44% to $107.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$378.4 million, marking a year-over-year decrease of 316.37%. This contributed to the annual value of -$87.3 million for FY2024, which is 87.77% up from last year.
  • Latest data reveals that Novavax reported Cash from Operations of $107.8 million as of Q3 2025, which was up 184.55% from -$127.5 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Cash from Operations peaked at $663.1 million during Q1 2021, and registered a low of -$342.4 million during Q4 2021.
  • For the 3-year period, Novavax's Cash from Operations averaged around -$91.5 million, with its median value being -$144.8 million (2024).
  • Within the past 5 years, the most significant YoY rise in Novavax's Cash from Operations was 2,969.26% (2021), while the steepest drop was 2,087.83% (2021).
  • Novavax's Cash from Operations (Quarterly) stood at -$342.4 million in 2021, then skyrocketed by 65.59% to -$117.8 million in 2022, then plummeted by 50.05% to -$176.8 million in 2023, then climbed by 2.03% to -$173.2 million in 2024, then spiked by 174.44% to $107.8 million in 2025.
  • Its Cash from Operations stands at $107.8 million for Q3 2025, versus -$127.5 million for Q2 2025 and -$185.5 million for Q1 2025.